Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice

Gut Pathogens

David Keller¹  Kelly D Karpa³  Wallace H Greene²  Jeffrey S Small³  Leo R Fitzpatrick³ 

[1] Ganeden Biotech Inc., 5915 Landerbrook Drive, Suite 304, Mayfield Heights OH 44124, USA;Department of Pathology, Penn State College of Medicine, PO Box 850, Hershey, PA 17033, USA;Department of Pharmacology, Penn State College of Medicine, 1214 Research Boulevard, Hummelstown, PA 17036, USA

关键词: mice;    colitis;    probiotics;    Clostridium difficile;   

Others  :  828887
DOI  :  10.1186/1757-4749-3-16

 received in 2011-09-26, accepted in 2011-10-20,  发布年份 2011

【 摘 要 】

Background

Probiotics have beneficial effects in rodent models of Clostridium difficile (C. diffiicle)-induced colitis. The spore forming probiotic strain Bacillus Coagulans GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and immune-modulating effects in vitro. Our goal was to determine if BC30 improved C. difficile-induced colitis in mice. Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or BC30 (2 × 10⁹ CFU per day). Mice in the C. difficile groups received an antibiotic mixture (study days 5 to 8 in the drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The C. difficile strain VPI 10463 was given by gavage at 10⁴ CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses.

Results

All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive. On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in the BC30/C. difficile group, as compared to the vehicle/C. diffcile group (13.0%). On study day 16, 23.8% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this day, the stool consistency score for the BC30/C. difficile group (1.1 ± 0.2) was significantly lower (p < 0.05) than for the vehicle/C. difficile cohort (1.9 ± 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema, leukocyte influx) that was present following C. difficile infection. Colonic MIP-2 chemokine contents (pg/2 cm colon) were: 10.2 ± 0.5 (vehicle/no C. difficile), 24.6 ± 9.5 (vehicle/C. difficile) and 16.3 ± 4.3 (BC30/C. difficle).

Conclusion

The probiotic BC30 improved some parameters of C. difficile-induced colitis in mice. BC30 prolonged the survival of C. diffiicle infected mice. Particularly, this probiotic improved the stool consistency of mice, in this infectious colitis model.

【 授权许可】

   
2011 Fitzpatrick et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Johnson S, Gerding DN: Clostridium difficile-associated diarrhea. Clin Infect Dis 1998, 26:1027-1034.
• [2]Kelly CP, Pothoulakis C, Lamont JT: Clostridium difficile colitis. N Eng J Med 1994, 330:257-262.
• [3]Pothoulakis C, Lamont JT: Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001, 28:G178-G183.
• [4]Jefferson KK, Smith MF, Bobak DA: Roles of intracellular calcium and NF-κB in the clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 1999, 165:5183-5191.
• [5]Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ: NF-κB activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with clostridium difficile toxin A. Scand J Immunol 2006, 63:453-460.
• [6]Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP: A mouse model of clostridium difficile-associated disease. Gastroenterology 2008, 135:1984-1992.
• [7]Bartlett JG: Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984, 6(Suppl 1):S235-S241.
• [8]Surawicsz CM, McFarland LV, Elmer G, Chinn J: Treatment of recurrent clostridium difficile colitis with vancomycin and saccharomyces boulardii. Am J Gastroenterol 1989, 84:1285-1287.
• [9]McFarland LV, Surawicsz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al.: A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA 1994, 271:1913-1918.
• [10]Surawicsz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmaker S, Bowen K, Borjal D, Elmer GW: The search for a better treatment for recurrent clostridium difficile disease: use of high-dose vancomycin combined with saccharomyces boulardii. Clin Infect Di 2000, 31:1012-1017.
• [11]Kimmey MB, Elmer GW, Surawicsz CM, McFarland LV: Prevention of further recurrences of clostridium difficile colitis with saccharomyces boulardii. Dig Dis Sci 1990, 35:897-901.
• [12]Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB: Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004, 127:1474-1487.
• [13]Fedorak RN, Madsen KL: Probiotics and the management of inflammatory bowel disease. Inflam Bowel Dis 2004, 10:286-299.
• [14]Shanahan F: Physiological basis for novel drug therapies to treat the inflammatory bowel diseases: I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005, 28:G417-G421.
• [15]Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun W: In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br J Nutrit 2008, 100:530-541.
• [16]Kaur S, Vaishnavi C, Ray P, Kochhar R, Prasad KK: Effect of biotherapeutics on cyclosporin-induced clostridium difficile infection in mice. J Gastroenterol Hepatol 2010, 25:832-838.
• [17]Keller D, Farmer S, McCartney AL, Gibson G: Bacillus coagulans as a probiotic. Food Science and Technology Bulletin: Functional Foods 2010, 7:103-109.
• [18]Needle C: Gut Instinct: AIDS Healthcare Foundation Trains a Research Lens on Probiotics. A&U Magazine, Albany NY 2010.
• [19]Jensen GS, Benson KF, Carter SG, Endres JR: Ganeden BC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010, 11:15. BioMed Central Full Text
• [20]Kim H, Rhee SH, Pothoulakis C, Lamont JT: Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 2007, 133:857-866.